{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:26:43Z","timestamp":1776378403558,"version":"3.51.2"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clon.2022.11.008","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:38:12Z","timestamp":1669379892000},"page":"163-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?"],"prefix":"10.1016","volume":"35","author":[{"given":"E.","family":"Carrasco-Esteban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barrionuevo-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dom\u00ednguez-Rull\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"G\u00f3mez-Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ferri-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"S\u00e1ez-Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Zalabarr\u00eda-Zarrabeitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2022.11.008_bib1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bju.12950","article-title":"Renal cell cancer histological subtype distribution differs by race and sex: RCC histology varies by race and sex","volume":"117","author":"Lipworth","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2022.11.008_bib2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.clon.2022.11.008_bib3","series-title":"Devita, Hellman, and Rosenberg\u2019s cancer: principles & practice of oncology. 10th edition","year":"2015"},{"key":"10.1016\/j.clon.2022.11.008_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.seminoncol.2016.09.001","article-title":"Genetic predisposition to kidney cancer","volume":"43","author":"Schmidt","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajur.2016.08.006","article-title":"Metastasis in renal cell carcinoma: biology and implications for therapy","volume":"3","author":"Gong","year":"2016","journal-title":"Asian J Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S1470-2045(21)00665-3","article-title":"Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?","volume":"22","author":"Magn\u00e9","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib7","first-page":"179","article-title":"Renal cell carcinoma: diagnosis and management","volume":"99","author":"Gray","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clon.2022.11.008_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urolonc.2015.05.020","article-title":"Imaging of renal cell carcinoma","volume":"34","author":"Sankineni","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00201","article-title":"The place of FDG PET\/CT in renal cell carcinoma: value and limitations","volume":"6","author":"Liu","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jacr.2017.04.028","article-title":"Management of the incidental renal mass on CT: a White Paper of the ACR Incidental Findings Committee","volume":"15","author":"Herts","year":"2018","journal-title":"J\u00a0Am Coll Radiol"},{"key":"10.1016\/j.clon.2022.11.008_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvir.2021.100774","article-title":"Renal mass biopsy","volume":"24","author":"Quencer","year":"2021","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.clon.2022.11.008_bib12","series-title":"National comprehensive cancer Network. Kidney cancer (version 4.2022)","year":"2021"},{"key":"10.1016\/j.clon.2022.11.008_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13014-021-01937-9","article-title":"Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma","volume":"16","author":"Liu","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in\u00a0vitro and in\u00a0vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","article-title":"Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model","volume":"50","author":"Walsh","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clon.2022.11.008_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.critrevonc.2017.07.004","article-title":"Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease","volume":"117","author":"Alongi","year":"2017","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.clon.2022.11.008_bib19","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"Meerleer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib20","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.24238","article-title":"Complexity of tumor vasculature in clear cell renal cell carcinoma","volume":"115","author":"Qian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/cco.2017.06.30","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases","volume":"6","author":"Kothari","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clon.2022.11.008_bib23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4161\/cbt.4.9.1915","article-title":"Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis","volume":"4","author":"Sathishkumar","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clon.2022.11.008_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1541-7786.MCR-12-0117","article-title":"State of the science: an update on renal cell carcinoma","volume":"10","author":"Jonasch","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clon.2022.11.008_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clon.2022.11.008_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/17843286.2016.1201614","article-title":"Abscopal effect in metastatic renal cell carcinoma","volume":"72","author":"Van de Walle","year":"2017","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.clon.2022.11.008_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/02841860600604611","article-title":"Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma","volume":"45","author":"Wers\u00e4ll","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.urology.2015.08.012","article-title":"Contemporary trends in the utilization of radiotherapy in patients with renal cell carcinoma","volume":"86","author":"Shaikh","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.clon.2022.11.008_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00365597709179965","article-title":"Preoperative irradiation in the treatment of renal adenocarcinoma","volume":"11","author":"Juusela","year":"1977","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.clon.2022.11.008_bib31","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/1097-0142(197311)32:5<1056::AID-CNCR2820320505>3.0.CO;2-M","article-title":"Proceedings: Carcinoma of the kidney","volume":"32","author":"van der Werf-Messing","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib32","first-page":"43","article-title":"Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials","volume":"199","author":"Lenis","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib33","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq028","article-title":"Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials","volume":"21","author":"Tunio","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.euo.2018.10.003","article-title":"Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis","volume":"2","author":"Rodr\u00edguez-Fern\u00e1ndez","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1464-410X.1969.tb09903.x","article-title":"Post-operative irradiation in the treatment of renal cell carcinoma","volume":"41","author":"Peeling","year":"1969","journal-title":"Br J Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1097-0142(197001)25:1<26::AID-CNCR2820250106>3.0.CO;2-4","article-title":"Renal cell carcinoma. Natural history and results of treatment","volume":"25","author":"Rafla","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G","article-title":"Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases","volume":"28","author":"Skinner","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1464-410X.1973.tb12152.x","article-title":"The value of radiotherapy in the treatment of hypernephroma \u2013 a clinical trial","volume":"45","author":"Finney","year":"1973","journal-title":"Br J Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0360-3016(87)90283-5","article-title":"Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group","volume":"13","author":"Kjaer","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(92)90352-U","article-title":"The value of postoperative irradiation in renal cell cancer","volume":"24","author":"Stein","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1148\/radiology.193.3.7972814","article-title":"Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT","volume":"193","author":"Kao","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.clon.2022.11.008_bib42","first-page":"380","article-title":"The value of postoperative radiotherapy in advanced renal cell cancer","volume":"45","author":"Makarewicz","year":"1998","journal-title":"Neoplasma"},{"key":"10.1016\/j.clon.2022.11.008_bib43","first-page":"17","article-title":"Post operative radiotherapy improves disease free but not overall survival in high risk renal cell carcinoma patients","volume":"12","author":"Safwat","year":"2000","journal-title":"J\u00a0Egypt Nat Cancer Inst"},{"key":"10.1016\/j.clon.2022.11.008_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/030089160609200303","article-title":"The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience","volume":"92","author":"Ulutin","year":"2006","journal-title":"Tumori"},{"key":"10.1016\/j.clon.2022.11.008_bib45","first-page":"1429","article-title":"Is post operative radiotherapy justified for completely resected locally advanced renal cell cancers?","volume":"4","author":"Abdulmoniem","year":"2013","journal-title":"J\u00a0Cancer Ther"},{"key":"10.1016\/j.clon.2022.11.008_bib46","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11255-015-1093-y","article-title":"Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study","volume":"47","author":"Eminaga","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clon.2022.11.008_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma","volume":"4","author":"Flanigan","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib48","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/cncr.21410","article-title":"A\u00a0phase II trial of palliative radiotherapy for metastatic renal cell carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib49","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2217\/fon-2017-0536","article-title":"Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA","volume":"14","author":"Haque","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/COC.0000000000000329","article-title":"Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations","volume":"41","author":"Correa","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib51","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cancers13133129","article-title":"Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience","volume":"13","author":"Grelier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2022.11.008_bib52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clon.2022.11.008_bib53","first-page":"e6","article-title":"The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT)","volume":"3","author":"\u00ae","year":"2007","journal-title":"Biomed Imaging Interv J"},{"key":"10.1016\/j.clon.2022.11.008_bib54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/01.coc.0000145289.57705.07","article-title":"Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma","volume":"27","author":"Beitler","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wers\u00e4ll","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib56","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/02841860802123196","article-title":"Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney","volume":"47","author":"Svedman","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/ol.2014.2129","article-title":"Novel application of stereotactic ablative radiotherapy using CyberKnife\u00ae for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: initial clinical experiences","volume":"8","author":"Lo","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clon.2022.11.008_bib58","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clon.2016.04.002","article-title":"Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience","volume":"28","author":"Chang","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib60","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jrr\/rrab031","article-title":"Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute","volume":"62","author":"Yamamoto","year":"2021","journal-title":"J\u00a0Radiat Res"},{"key":"10.1016\/j.clon.2022.11.008_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.adro.2019.07.018","article-title":"Utilization of stereotactic ablative body radiation therapy for intact renal cell carcinoma: trends in treatment and predictors of outcome","volume":"5","author":"Wegner","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib63","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A\u00a0prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib64","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2013.06.218","article-title":"A\u00a0phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma","volume":"87","author":"McBride","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2014.07.043","article-title":"Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity","volume":"90","author":"Pham","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib67","first-page":"771","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2022.11.008_bib69","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/j.ijrobp.2010.07.464","article-title":"Results of a phase i dose escalation study of stereotactic radiosurgery for primary renal tumors","volume":"78","author":"Kaplan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13014-014-0253-z","article-title":"Short communication: Timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT\/CT","volume":"9","author":"Jackson","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1553350607310546","article-title":"Renal radiosurgery: initial clinical experience with histological evaluation","volume":"14","author":"Ponsky","year":"2007","journal-title":"Surg Innov"},{"key":"10.1016\/j.clon.2022.11.008_bib72","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon.16.2","article-title":"Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma","volume":"12","author":"Siva","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib73","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.adro.2020.01.002","article-title":"Stereotactic body radiation therapy for the definitive treatment of early stage kidney cancer: a survival comparison with surgery, tumor ablation, and observation","volume":"5","author":"Grant","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib74","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib75","first-page":"104","article-title":"Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?","volume":"18","author":"R\u00fchle","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib76","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jvir.2019.11.009","article-title":"Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation","volume":"31","author":"Uhlig","year":"2020","journal-title":"J\u00a0Vasc Interven Radiol"},{"key":"10.1016\/j.clon.2022.11.008_bib77","first-page":"1097","article-title":"Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK","volume":"201","author":"Correa","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib78","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13014-016-0651-5","article-title":"Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma","volume":"11","author":"Yamamoto","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib80","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","article-title":"Radiation-associated kidney injury","volume":"76","author":"Dawson","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib81","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/spi.2005.3.4.0288","article-title":"Stereotactic radiosurgery for spinal metastases from renal cell carcinoma","volume":"3","author":"Gerszten","year":"2005","journal-title":"J\u00a0Neurosurg Spine"},{"key":"10.1016\/j.clon.2022.11.008_bib83","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2009.03.062","article-title":"Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy","volume":"76","author":"Nguyen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib84","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3171\/2012.8.SPINE12303","article-title":"Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma: Clinical article","volume":"17","author":"Balagamwala","year":"2012","journal-title":"J\u00a0Neurosurg Spine"},{"key":"10.1016\/j.clon.2022.11.008_bib85","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","article-title":"Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma","volume":"82","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib86","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/COC.0b013e31825d52b2","article-title":"Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma","volume":"36","author":"Ranck","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib88","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.21037\/jtd.2017.10.108","article-title":"Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma \u2014 a multicenter analysis of the German working group \u201cStereotactic Radiotherapy\u201d","volume":"9","author":"Hoerner-Rieber","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.clon.2022.11.008_bib89","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2022.11.008_bib90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.radonc.2018.04.028","article-title":"Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005\u20132014","volume":"127","author":"Stenman","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib91","first-page":"70","article-title":"Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma","volume":"201","author":"Franzese","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib92","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.11.008_bib93","article-title":"Treatment outcome of metastatic lesions from renal cell carcinoma undergoing extra-cranial stereotactic body radiotherapy: the TOGETHER retrospective study","volume":"22","author":"Buti","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.clon.2022.11.008_bib94","first-page":"29","article-title":"Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: a multi-institutional experience","volume":"7","author":"Singh","year":"2020","journal-title":"J\u00a0Radiosurg SBRT"},{"key":"10.1016\/j.clon.2022.11.008_bib95","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1007\/s00345-021-03742-1","article-title":"Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy","volume":"39","author":"Liu","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib96","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib97","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s12094-021-02574-0","article-title":"Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?","volume":"23","author":"Marvaso","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib98","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","article-title":"The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group","volume":"38","author":"Franzese","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clon.2022.11.008_bib99","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13014-015-0528-z","article-title":"Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT)","volume":"10","author":"Altoos","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib100","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/j.prro.2015.05.004","article-title":"Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant?","volume":"5","author":"Amini","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3171\/2015.8.SPINE15844","article-title":"Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of phase I\/II trials","volume":"24","author":"Ghia","year":"2016","journal-title":"J\u00a0Neurosurg Spine"},{"key":"10.1016\/j.clon.2022.11.008_bib102","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clon.2022.11.008_bib103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.clon.2022.11.008_bib104","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC)","volume":"38","author":"Hammers","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1200\/JCO.2021.39.6_suppl.277","article-title":"Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: the RAPPORT trial","volume":"39","author":"Siva","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.008_bib106","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2022.11.008_bib107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12967-014-0262-6","article-title":"Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response","volume":"12","author":"Ridolfi","year":"2014","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clon.2022.11.008_bib108","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12885-021-08088-w","article-title":"Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial","volume":"21","author":"Spaas","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522005416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522005416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:02Z","timestamp":1760543522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522005416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0936655522005416"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.11.008","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}